Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas ...
From 7% to nearly 9% of patients with advanced cancer were found to harbor a germline variant with targeted therapeutic actionability in the first study of its kind. The study involved 11,974 patients ...
Hereditary breast cancer results from inherited mutations, primarily in BRCA1 and BRCA2, increasing lifetime cancer risk. Additional genes like TP53, PTEN, PALB2, CHEK2, and ATM also contribute to ...
About The Study: This study identified 5.05% of individuals carrying pathogenic or likely pathogenic variants, suggesting a higher-than-expected prevalence of key cancer susceptibility genes in a ...
Germline pathogenic variants contribute to 15%-20% of ovarian cancer cases, with BRCA1/2 mutations accounting for 65%-85% of these cases. Disparities in genetic testing uptake exist across racial, ...
Hosted on MSN
Somatic and germline mutation rates covary linearly across ciliates and mammals, study finds
In a study published in Current Biology on August 14, Prof. Miao Wei's team at the Institute of Hydrobiology (IHB) of the Chinese Academy of Sciences and Prof. Zhang Jianzhi's team at the University ...
About The Study: In this secondary analysis of the WISDOM trial, a randomized clinical trial that enrolled women without breast cancer ages 40 to 74, criteria-independent genetic testing in a ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results